Roche Reports Positive P-II Results of Dual GLP-1/GIP Agonist CT-388 in Obesity

Shots: Roche reported positive topline results from the P-II (CT388-103) study evaluating CT-388, an investigational dual GLP-1/GIP receptor agonist, for the treatment of obesity Once-weekly CT-388 (SC) achieved a statistically significant PBO-adjusted weight loss of 22.5% (p<0.001; efficacy estimand) at 48 wks. at the highest dose (24 mg), with no weight-loss plateau observed; 54% of…

ByPrince GiriJanuary 28, 2026

NEWS

Novo Nordisk Reports the US FDA Approval of Oral Wegovy for Weight Management

Shots: FDA has approved Wegovy (25mg, QD, PO) for weight loss, chronic weight management & major adverse CV events risk reduction in adults with obesity/overweight; US availability expected in early Jan 2026. Regulatory filing is made to the EMA & other authorities in H2’25 Approval was based on the P-IIIb (OASIS 4) trial assessing oral…

ByRidhi RastogiDecember 24, 2025

NEWS

Eli Lilly Reports P-III (TRIUMPH-4) Trial Data on Retatrutide for Weight Management

Shots: Trial assessed Lilly’s retatrutide (9 & 12mg) + lifestyle intervention in adults with obesity or overweight & knee osteoarthritis, & without diabetes, meeting its co-1EPs with 26.4% (9mg) & 28.7% (12mg) vs 2.1% weight loss & reduced WOMAC pain by 4.5 & 4.4 vs 2.4 points It also reduced known CV risk markers &…

ByRidhi RastogiDecember 12, 2025

NEWS

Innovent Biologics Reports P-III (GLORY-2) Trial Data on Mazdutide for Obesity

Shots: The P-III (GLORY-2) trial assessed mazdutide (9mg) plus lifestyle intervention vs PBO in 462 Chinese adults with obesity (BMI ≥30kg/m²), incl. 16% with T2D, with an NDA submission to the NMPA planned in the near term Trial met its 1EP, showing continuous weight loss with no plateau through Wk. 60, with pts achieving a…

ByRidhi RastogiNovember 20, 2025

NEWS

Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)

Shots: Endevica Bio conducting P-II study in collaboration with WuXi Clinical reported the dose administration of B07 in first patient to prevent weight loss in cancer patients diagnosed with stage 4 metastatic colorectal cancer undergoing CT In 2024, Endevica Bio completed its P-I study, with early results showing strong safety and efficacy. In current P-II…

ByPrince GiriApril 18, 2025

NEWS

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Shots: Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete…

ByRidhi RastogiApril 2, 2025

NEWS

Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients

Shots: Novo Nordisk has reported P-III (REDEFINE 2) trial data assessing CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, QW, SC) vs PBO in 1,206 obese/overweight pts (~102Kg) and type 2 diabetes for 68wks., and followed flexible dosing protocol with 61.9% pts reaching highest dose after 68wks. Trial met its co-1EPs demonstrated 15.7% superior weight loss…

ByRidhi RastogiMarch 11, 2025

THOUGHTSPOT

Tearing the Silence: Addressing Common Postpartum Concerns

Bringing a new life into this world is miraculous and rewarding. Gazing into your baby’s tiny eyes while holding them is blissful. Yet this joy and sense of fulfillment come with challenges. Support, guidance and health education are needed the most in the postpartum period to empower women to make informed choices about their own…

ByJehan AraAugust 8, 2024

THOUGHTSPOT

Managing Chronic Conditions: Medication, Supplements, and Personalized Care Plans

Statistics show that at least 129 million people in the United States have a chronic illness. To effectively deal with chronic illnesses, one needs a thorough approach that includes customized supplements and medication. The management of these prolonged conditions requires consistent attention to prevent complexities while ensuring better living standards for patients. Continue reading to learn about…

ByIgor ZagradaninJuly 26, 2024

THOUGHTSPOT

How to Find the Best Ozempic Suppliers from Canada?

These days, Ozempic is one of the most popular prescription medications for blood glucose control (or, in other words, blood sugar control). With its help, a great number of people living with diabetes mellitus manage to control their blood glucose levels (or, in other words, blood sugar levels) easily and effectively. But what differentiates Ozempic…

ByOwen ClarkeMay 31, 2024

Roche Reports Positive P-II Results of Dual GLP-1/GIP Agonist CT-388 in Obesity

Novo Nordisk Reports the US FDA Approval of Oral Wegovy for Weight Management

Eli Lilly Reports P-III (TRIUMPH-4) Trial Data on Retatrutide for Weight Management

Innovent Biologics Reports P-III (GLORY-2) Trial Data on Mazdutide for Obesity

Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Novo Nordisk Reveals P-III (REDEFINE 2) Trial data of CagriSema for Weight Loss in Obese/Overweight and T2D Patients

Tearing the Silence: Addressing Common Postpartum Concerns

Managing Chronic Conditions: Medication, Supplements, and Personalized Care Plans

How to Find the Best Ozempic Suppliers from Canada?

Contact US

FOLLOW US